Rekombinanter IL5 (Mepolizumab Biosimilar) Antikörper

Produktnummer ABIN7487818

Dieser Mammalian Cells Monoklonal Antikörper erkennt spezifisch IL5 (Mepolizumab Biosimilar) in ELISA. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für Rekombinanter IL5 (Mepolizumab Biosimilar) Antikörper (ABIN7487818)

Target: IL5 (Mepolizumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Mammalian Cells

Klonalität: Monoklonal

Konjugat: Dieser IL5 (Mepolizumab Biosimilar) Antikörper ist unkonjugiert

Applikation: ELISA

Güteklasse: Research Grade

Produktdetails anti-IL5 (Mepolizumab Biosimilar) Antikörper

Expressionssystem: Mammalian cells

Verwendungszweck: Mepolizumab Biosimilar - Anti-IL5 mAb

Produktmerkmale: Antibody Type: IgG1-kappa

Aufreinigung: Recombinant antibody expressed in mammalien cells and purified.

Isotyp: IgG1 kappa

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS pH 7.5

Lagerung: -80 °C

Informationen zur Lagerung: store at -80°C

Details zu IL5 (Mepolizumab Biosimilar)

Target: IL5 (Mepolizumab Biosimilar)

Substanzklasse: Biosimilar

Hintergrund: SB-240563
Mepolizumab is a fully humanized recombinant IgG1 kappa monoclonal antibody directed against IL-5 produced in Chinese hamster ovary cells. (EGPA) and eosinophilia syndrome (HES). The pathogenesis of eosinophils is complex, but IL-5 is considered a key eosinophilic factor, involved in the differentiation, recruitment, activation and prolonged survival of eosinophils in peripheral tissues. Activated eosinophils further stimulate the inflammatory response, and also induce tissue damage and promote fibrosis, all of which contribute to the multifactorial symptoms of eosinophilic disease. Mepolizumab is used to treat severe asthma.

CAS-Nummer: 196078-29-2